Four anticancer drugs (Olaparib (Lynparza), O; Cediranib, C; Durvalumab (Imfinzi), D; Tremelimumab, T) from AstraZeneca are expected to give hope to patients with platinum-resistant recurrent ovarian cancer for whom do not have available treatments.
At the 2021 ASCO Annual Meeting, Korean researchers including, Jung-Yun Lee, a professor at Yonsei University Hospital, announced the results of an umbrella study targeting patients with platinum-resistant recurrent ovarian cancer.
The study was conducted on 70 patients with platinum-resistant ovarian cancer with ≥ two lines of prior chemotherapy (CT) and ECOG 0/1.
Seventy patients were divided into five treatment arms based on HRD and PD-L1 expression and received treatment from December 2018 to October 2020.
For HRD+ patients, they tested ▲O+C ▲O+D, and for HRD- patients, they tested the role of biomarker-driven immunotherapy according to PD-L1 expression, ▲D+CT in patients with high PD-L1 expression, ▲D+T75+CT in patients with low PD-L1 expression, or ▲D+T300+CT in patients with low PD-L1 expression.
Among all patients, the objective response rate (ORR) was 35.7%, when HRD+, O+C was 50%, O+D was 35.7%, and when HRD-, D+CT was 20%, D+T75+CT was 33.3%, and D+T300+CT was 29.4%.
No treatment-related adverse events (TRAEs) leading to discontinuation of treatment, and no grade 5 TRAEs were observed.
Professor Lee said, “This is the first biomarker-driven umbrella study conducted on patients with platinum-resistant recurrent ovarian cancer,” and added, “This study provides preliminary evidence on the clinical benefits of biomarker-driven targeted treatment.”
